TAFINLAR (dabrafenib), in combination with MEKINIST (trametinib), protein kinase inhibitors

Insufficient clinical benefit to justify public funding of the TAFINLAR / MEKINIST combination for advanced non-small cell lung cancer carrying a BRAF V600 mutation.

• TAFINLAR and MEKINIST have been granted a marketing authorisation in combination for the treatment of advanced non-small cell lung cancer (NSCLC) carrying a BRAF V600 mutation.

• It is not possible to assess the clinical added value of the combination due to the lack of comparative data with respect to clinically relevant comparators, particularly in respect of overall survival compared to chemotherapy, even though this comparison was possible.

• This combination has no role in the treatment strategy for advanced NSCLC carrying a BRAF V600 mutation.